Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation

Journal of Clinical Immunology

Volumn 30, Issue 6, 2010, Pages 886-893

  Kumánovics, Attila ^a   Perkins, Sherrie L ^a,c   Gilbert, Heather ^a   Cessna, Melissa H ^b   Augustine, Nancy H ^a,c   Hill, Harry R ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b LDS HOSPITAL   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

Hyper IgE syndrome; Immunodeficiency; Job syndrome; Lymphoma; Melting analysis; STAT3

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; PREDNISONE; RITUXIMAB; STAT3 PROTEIN; VINCRISTINE;

ADULT; ARTICLE; ASPIRATION BIOPSY; CANCER STAGING; CASE REPORT; DRUG RESPONSE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPER IGE SYNDROME; IMMUNOHISTOCHEMISTRY; INFECTION; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHROMOSOME DISORDERS; HUMANS; JOB'S SYNDROME; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MUTATION; STAT3 TRANSCRIPTION FACTOR;

EID: 78651336297     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9452-z     Document Type: Article

References (58)

1. Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, et al. Hyper-IgE syndrome with recurrent infections-an autosomal dominant multisystem disorder. N Engl J Med. 1999;340:692-702.
2. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. Immunol Rev. 2005;203:244-50.
3. Woellner C, Gertz EM, Schaffer AA, Lagos M, Perro M, Glocker EO, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125:424-32. e428.
4. Davis SD, Schaller J, Wedgwood RJ. Job's syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet. 1966;1:1013-5.
5. Holland SM, De Leo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357:1608-19.
6. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058-62.
7. Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T (H) 17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181-7.
8. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205:1551-7.
9. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T (H) 17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773-6.
10. Jiao H, Toth B, Erdos M, Fransson I, Rakoczi E, Balogh I, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol. 2008;46:202-6.
11. Minegishi Y, Karasuyama H. Hyperimmunoglobulin E syndrome and tyrosine kinase 2 deficiency. Curr Opin Allergy Clin Immunol. 2007;7:506-9.
12. Kumánovics A, Wittwer CT, Pryor RJ, Augustine NH, Leppert MF, Carey JC, et al. Rapid molecular analysis of the STAT3 gene in Job syndrome of hyper-IgE and recurrent infectious diseases. J Mol Diagn. 2010;12:213-9.
13. Al Khatib S, Keles S, Garcia-Lloret M, Karakoc-Aydiner E, Reisli I, Artac H, et al. Defects along the T (H) 17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol. 2009;124:342-8. e341-345.
14. Renner ED, Puck JM, Holland SM, Schmitt M, Weiss M, Frosch M, et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. J Pediatr. 2004;144:93-9.
15. Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009;124:1289-302. e1284.
16. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361:2046-55.
17. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25:745-55.
18. Woellner C, Schaffer AA, Puck JM, Renner ED, Knebel C, Holland SM, et al. The hyper IgE syndrome and mutations in TYK2. Immunity. 2007;26:535. author reply 536.
19. Belada D, Smolej L, Stepankova P, Kralickova P, Freiberger T. Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: successful treatment with risk-adapted rituximab-based immunochemotherapy. Leuk Res. 2010;34: e232-4.
20. Chang CH, Hsu YH. Hyper-IgE syndrome with Epstein-Barr virus associated extranodal NK/T cell lymphoma of skin. Kaohsiung J Med Sci. 2010;26:206-10.
21. Bale Jr JF, Wilson JF, Hill HR. Fatal histiocytic lymphoma of the brain associated with hyperimmunoglobulinemia-E and recurrent infections. Cancer. 1977;39:2386-90.
22. Nester TA, Wagnon AH, Reilly WF, Spitzer G, Kjeldsberg CR, Hill HR. Effects of allogeneic peripheral stem cell transplantation in a patient with job syndrome of hyperimmunoglobulinemia E and recurrent infections. Am J Med. 1998;105:162-4.
23. Leonard GD, Posadas E, Herrmann PC, Anderson VL, Jaffe ES, Holland SM, et al. Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review. Leuk Lymphoma. 2004;45:2521-5.
24. Clark TJ, Herod JJ, Kehoe S, Luesley DM. The development of invasive vulvar cancer in a patient with Job's syndrome, a rare immunodeficient condition. Br J Obstet Gynaecol. 1998;105:468-70.
25. Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BK, Matsuoka M, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA. 1997;94:13897-902.
26. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009;324:1713-6.
27. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, et al. Function of mitochondrial Stat3 in cellular respiration. Science. 2009;323:793-7.
28. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood. 2001;98:762-70.
29. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168:466-74.
30. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC. Focus on multiple myeloma. Cancer Cell. 2004;6:439-44.
31. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11:623-9.
32. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008;111:1515-23.
33. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701-13.
34. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81-3.
35. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295-303.
36. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-15.
37. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97-105.
38. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000-8.
39. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest. 2004;114:720-8.
40. Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, Mustelin T, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci USA. 1997;94:6764-9.
41. Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood. 2006;108:1058-64.
42. Onal IK, Kurt M, Altundag K, Aksoy S, Dincer M, Gullu I. Peripheral T-cell lymphoma and Job's syndrome: a rare association. Med Oncol. 2006;23:141-4.
43. Ruusala A, Aspenstrom P. Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology. FEBS Lett. 2004;572:159-66.
44. Randall KL, Lambe T, Johnson AL, Treanor B, Kucharska E, Domaschenz H, et al. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol. 2009;10:1283-91.
45. Lei JY, Wang Y, Jaffe ES, Turner ML, Raffeld M, Sorbara L, et al. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes simplex virus infection, and cutaneous T-cell lymphoma. Am J Dermatopathol. 2000;22:524-9.
46. Idbaih A, Carvalho Silva R, Criniere E, Marie Y, Carpentier C, Boisselier B, et al. Genomic changes in progression of low-grade gliomas. J Neurooncol. 2008;90:133-40.
47. Kang JU, Koo SH, Kwon KC, Park JW. Frequent silence of chromosome 9p, homozygous DOCK8, DMRT1 and DMRT3 deletion at 9p24.3 in squamous cell carcinoma of the lung. Int J Oncol. 2010;37:327-35.
48. Takahashi K, Kohno T, Ajima R, Sasaki H, Minna JD, Fujiwara T, et al. Homozygous deletion and reduced expression of the DOCK8 gene in human lung cancer. Int J Oncol. 2006;28:321-8.
49. Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, et al. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell. 2003;112:673-84.
50. Gorin LJ, Jeha SC, Sullivan MP, Rosenblatt HM, Shearer WT. Burkitt's lymphoma developing in a 7-year-old boy with hyper-IgE syndrome. J Allergy Clin Immunol. 1989;83:5-10.
51. Einsele H, Saal JG, Dopfer R, Niethammer D, Waller HD, Muller CA. Highly malignant non-Hodgkin's lymphoma in hyper-IgE syndrome. Dtsch Med Wochenschr. 1990;115:1141-4.
52. Kowalchuk RM. Case of the season. Job's syndrome with superimposed lymphoma. Semin Roentgenol. 1996;31:254-6.
53. Lin SJ, Huang JL, Hsieh KH. Hodgkin's disease in a child with hyperimmunoglobulin E syndrome. Pediatr Hematol Oncol. 1998;15:451-4.
54. Huber KK, Cole KJ, Greene JN, Sandin RL, Vincent AL, Brown R. Malignancies associated with hyper-IgE syndrome: case and review. Infect Dis Clin Practice. 2000;9:128-30.
55. Mosseri R, Finkelstein Y, Monselize Y, Garty BZ. Large T-cell lymphoma in a 13-year-old girl with hyperimmunoglobulinemia E syndrome. Pediatr Allergy Immunol. 2002;13:143-6.
56. Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK. Extensive xanthelasma associated with anaplastic large cell lymphoma and hyperimmunoglobulin E syndrome. Int J Dermatol. 2003;42:944-6.
57. Kashef MA, Kashef S, Handjani F, Karimi M. Hodgkin lymphoma developing in a 4.5-year-old girl with hyper-IgE syndrome. Pediatr Hematol Oncol. 2006;23:59-63.
58. Wallet N, Ghez D, Delarue R, Suarez F, Rubio MT, Fischer A, et al. Diffuse large B-cell lymphoma in hyperimmunoglobulinemia E syndrome. Clin Lymphoma Myeloma. 2007;7:425-7.